A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL

  检 索： 期刊名称 ISSN         高级检索

期刊名称：REGENERATIVE MEDICINE ISSN： 1746-0751 出版频率： Monthly 出版社： FUTURE MEDICINE LTD, UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, ENGLAND, N3 1QB   出版社网址： http://www.futuremedicine.com/?cookieSet=1 期刊网址： http://www.futuremedicine.com/loi/rme 影响因子： 3.806 主题范畴： CELL & TISSUE ENGINEERING;    ENGINEERING, BIOMEDICAL 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Aims & Scope Improved healthcare has resulted in dramatic demographic changes in developed countries, causing an increase in the prevalence of diseases associated with aging. Many significant human diseases arising from the loss or dysfunction of specific cell types in the body, such as Parkinson's disease, diabetes and cancer, are becoming increasingly common. Stem cell research and regenerative medicine offers unique opportunities for developing new therapeutic approaches to prevent and treat these debilitating and life-threatening diseases, and new ways to explore fundamental questions of biology. The current optimism over potential stem cell therapies is driven by new understandings of genetics and developmental biology. Gradually, the curative and regenerative potential that lies in harnessing stem cells is being realized. Regenerative Medicine (ISSN: 1746-0751) provides a forum to address the important challenges and advances in stem cell research and regenerative medicine, delivering this essential information in concise, clear and attractive article formats ?vital to an increasingly time-constrained community. Coverage includes: Developmental biology and reproductive medicine Derivation and maintenance of stem cell lineages Potential applications for stem cell-based strategies in pathological conditions Stem cell clonality and emerging technologies Stem cell plasticity and pluripotency Tissue engineering and characterization of engineered tissues Medical device and artificial organ development Technologies that will maintain, improve or restore the function of diseased organs Gene therapies for inherited diseases Drug development and stem cells Regulatory issues concerning the derivation of stem cells Ethical and legal considerations Despite substantial developments in our knowledge and understanding of stem cell biology and regenerative medicine, the field is in its infancy. The next few decades will unveil the true potential of this emerging specialty. Regenerative Medicine will provide a critical overview of these advances as they unfold and explore their potential relevance in the clinical setting. Back to top Indexing EMBASE/Excerpta Medica Chemical Abstracts MEDLINE/Index Medicus  Biological Abstracts BIOSIS Previews Science Citation Index Expanded?(SciSearch?/SUP>) Biotechnology Citation Index? Journal Citation Reports/Science Edition?/SUP> Instructions to Authors Author Guide We accept unsolicited manuscripts for publication in Future Medicine journals. All review articles published in the journals are subject to rigorous peer-review by independent experts in the field. If you are interested in submitting an article, please contact the Commissioning Editor of the relevant journal with a brief proposal and article outline in the first instance. We also have an active commissioning program whereby the Commissioning Editor, under the advice of the Editorial Advisory Board, solicits articles for publication by Future Medicine. The following guidelines (PDF files) are provided to assist authors in the preparation of their manuscript. Future series Future Cardiology Future HIV Therapy Future Lipidology Future Microbiology Future Neurology Future Oncology Future Rheumatology Future Virology Health series Aging Health Women's Health Biomarkers in Medicine General Guidelines (reviews, perspectives, technology reports, special reports) Conference Report Editorial  Nanomedicine General Guidelines (reviews, perspectives, technology reports, special reports) Company Profile Conference Report Personalized Medicine General Guidelines (reviews, perspectives, technology reports, special reports) Research Report (original papers) Company Profile Conference Report Editorial Pharmacogenomics General Guidelines (reviews, perspectives, technology reports, special reports) Research Report (original papers) Company Profile Conference Report Editorial Regenerative Medicine General Guidelines (review, perspectives, technology reports, special reports) Company Profile Guidelines Conference Report Guidelines Therapy General Guidelines References The Future Medicine EndNote style for references is available here (compatible with Mac EndNote 9). Submission Please submit manuscripts in Microsoft Word 2000 format via e-mail to the Commissioning Editor of the relevant journal. Figures should be submitted as Microsoft PowerPoint, Adobe Illustrator or Photoshop (*.eps). Graphs and charts can also be submitted as Microsoft Excel. Copyright As the author of your manuscript, you are responsible for obtaining permissions to use material owned by others. Since the permission-seeking process can be time-consuming, it is wise to request permission as soon as possible. A template permission letter is available upon request by contacting the Commissioning Editor of the relevant journal. Please send us photocopies of letters or forms granting you permission for the use of copyrighted material so that we can see that any special requirements with regard to wording and placement of credits are fulfilled. Please keep the originals for your files. Editorial Board   Senior Editor Stephen L Minger, Director, Stem Cell Biology Laboratory, Wolfson Centre for Age Related Diseases, King's College London, UK In 2002, together with Dr Susan Pickering and Professor Peter Braude, Dr Minger was awarded one of the first two licenses granted by the Human Fertilisation and Embryology Authority for the derivation of human emybryonic stem (ES) cells. His group subsequently generated the first human ES cell line in the UK and was one of the first groups to deposit human ES cells into the UK Stem Cell Bank. Dr Minger received his BA in Psychology from the University of Minnesota and his PhD in Pathology (Neurosciences) in 1992 from the Albert Einstein College of Medicine. From 1992?994, he was a post-doctoral fellow in the laboratory of Prof. F Gage, Uni. of California, San Diego, where he first began to pursue research in neural stem cell biology. He moved his stem cell research programme to Guy's Hospital in 1996. Over the last 13 years his research group has worked with a wide range of somatic stem cell populations, as well as mouse and human ES cells. Associate Editors Professor Oliver Brüstle, Director, Institute of Reconstructive Neurobiology, University of Bonn, Germany Professor Brüstle's group at the University of Bonn were the first to receive a license to work on human embryonic stem cells in Germany. Subsequently, they went on to be the first to report on the therapeutic use of embryonic stem cell-derived neural cells to treat myelin disorders (Science 285, 754?56 [1999]). Professor Brüstle moved to the University in 1997 as Group Leader of the Department of Neuropathology, and became Director of the Institute of Reconstructive Neurobiology at the university in 2002. Prof. Brüstle is Co-Founder and Scientific Director of LIFE & BRAIN GmbH Bonn. His research focus is the use of embryonic stem cell-derived neural precursors for nervous system repair. Dr Olga Genbacev, Senior Scientist, Department of Tissue and Cell Biology, University of California San Francisco, CA, USA Dr Genbacev developed the new in vitro model of human placental explant culture that is now used by many investigators. She and Dr Susan Fisher  were the first to define the role of "physiological" hypoxia in the regulation of proliferation and differentiation of human placental trophoblast cells (Science, 1997) and to show that L-selectin and its ligands are involved in the initial steps of implantation in humans (Science, 2003).  She is currently a leading scientist in the project for derivation of new embryonic stem cell lines under feeder and animal product free conditions.  Dr Genbacev received her doctorate and honors degree in Biology at the University of Belgrade in 1975. She carried out her postdoctoral research in College de France (Paris) and at Yale University (USA). Between 1973 and 1991, she worked at the INEP Institute, associated with the University of Belgrade.  Dr Melinda Lako, Senior Lecturer in Stem Cell Biology, Institute of Human Genetics, Newcastle University, UK In 2003 Dr Lako established her own stem cell biology group at the Institute of Human Genetics, University of Newcastle. Dr Lako graduated from Tirana University, Albania in 1992 with a BSc in Biochemistry and Genetics. Following this, Dr Lako traveled to the UK to undertake a MSc in Environmental Sciences at Manchester University. Being inspired by the advances made in the Human Genome Project at the time, Dr Lako undertook a PhD training program at the Department of Human Genetics at the University of Newcastle where she cloned several members of the human WNT gene family and investigated their expression during early human emrbyogenesis. Dr Lako carried out her postdoctoral training at the University of Durham in Stem cell Biology where she investigated the differentiation of embryonic and hair follicle stem cells with Drs Nicholas Hole and Colin Jahoda. Dr Chris Mason, Regenerative Medicine Bioprocessing Group, Advanced Centre for Biochemical Engineering, University College London, UK Chris is at the forefront of the emerging field of stem cell and regenerative medicine bioprocessing plus is involved in a number of committees, working groups and initiatives related to both the academic and commercial advancement of stem cells and tissue engineering.  Originally graduating from Imperial College with a degree in molecular biology and St. Thomas’s Hospital Medical School with a medical degree, Chris then specialised in surgery. Chris is both a Fellow of the Royal College of Surgeons and a Fellow of the Royal Society of Medicine. In addition, he has a PhD in Biochemical Engineering (UCL), leads the Regenerative Medicine Bioprocess Group at UCL and has broad range of expertise in industrial consultancy. Furthermore, Chris has over 10 years experience at boardroom level of running technology companies and together with Dr. Stephen Minger is co-founder and co-organiser of the London Regenerative Medicine Network. Back to top Editorial Board Adams G, Harvard Medical School, MA, USA Ali R, University College London, UK Allsopp T, Stem Cell Sciences Ltd, UK Andrews PW, University of Sheffield, UK Anversa P, New York Medical College, NY, USA Atala A, Wake Forest University School of Med., NC, USA Baharvand H, Royan Institute, IR Barker R, Cambridge Centre for Brain Repair, UK Benvenisty N, Hebrew University of Jerusalem, IS Burt R, Northwestern University, IL, USA Cancedda R, Universit?di Genova, IT Cheng L, Johns Hopkins University School of Med., USA Choi U, NIAID, NIH, USA Chuang AT, GlaxoSmithKline, UK Colman A, ES Cell International, SG Dalton S, University of Georgia, GA, USA De Bari C, King's College London, UK Dunnett S, University of Cardiff, Wales, UK Dzierzak D, Erasmus University, NL Eaves C, British Columbia Cancer Agency, CA Fauza DO, Children's Hospital Boston, USA Freed CR, Univ. Colorado Hlth Sciences Ctr, USA Garry DJ, UT Southwestern Medical Center, TX, USA Habener J, Massachusetts Gen. Hospital, MA, USA Hamada H, Sapporo Medical University, JP Harris J, School of Law, University of Manchester, UK Hayek A, UCSD Whittier Institute, CA,USA Hirschi KK, Baylor College of Medicine,USA Hishikawa K, University of Tokyo, JP Hodges H, King's College London, UK Itskovitz-Eldor J, Technion, IS Itescu S, Columbia University, TX, USA Jaconi M, Geneva University Hospitals, CH Jorgensen C, Lapeyronie Hospital, FR Keith N, Cancer Research UK Beatson Labs, UK Keirstead HS, Reeve-Irvine Research Center, CA, USA Kloner R, Good Samaritan Hospital (USC), USA Koliatsos V, Johns Hopkins Uni. School of Med., USA Kormos R, McGowan Inst. for Regenerative Med., USA Krtolica A, Lawrence Berkeley Natl Lab., CA, USA Landry D, Columbia University, NY, USA Laurencin CT, The University of Virginia, USA Li R-K, Toronto General Hospital, CA Lowenstein P, Cedars-Sinai Med. Ctr & UCLA, CA, USA Mackay D, Genzyme, UK Madeddu P, Bristol Heart Institute, UK McNeish JD, Pfizer Global R&D, USA Nakatsuji N, Kyoto University, JP Okano H, Keio University, JP Oreffo R, University of Southampton, UK Patel A, McGowan Inst. for Regenerative Med., USA Polak JM, Imperial College London, UK Przyborski S, University of Durham, UK Salter B, University of East Anglia, UK Sanberg P, USF Coll. of Med., FL, USA Scharfmann R, INSERM, FR Semb H, Stem Cell Center, Lund University, SE Sharpe P, King’s College, London, UK Sheng HZ, Shanghai Second Medical Univ., CN Sidman R, Harvard Medical School, MA, USA Simon C, Valencia Stem Cell Bank, ES Snyder EY, The Burnham Institute, USA Soria B, Universidad Miguel Hernandez, ES Stevens MM, Imperial College London, UK Stojkovic M, Univ. Newcastle, UK Surani A, University of Cambridge, UK Sussman M, SDSU Heart Institute, USA Trounson A, Monash University, AU Uccelli A, University of Genoa, Italy Voltarelli J, University of São Paulo, BR Wilson IA, GE Healthcare Medical Diagnostics, UK Yoon Y–S, Tufts University School of Med., USA Young L, University of Nottingham, UK Zhu J, Shanghai Med. College–Fudan University, CN Zupanc GKH, International University Bremen, Germany